1177 related articles for article (PubMed ID: 28971779)
1. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, Docking Studies, Enzyme Inhibitory and Antiplatelet Aggregation Activities of New 1,3-Diphenyl-3-(Phenylthio)Propan-1-One Derivatives as Selective COX-2 Inhibitors.
Bayanati M; Daraei B; Zarghi A
Anticancer Agents Med Chem; 2023; 23(2):192-200. PubMed ID: 35692149
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
Abolhasani H; Zarghi A; Komeili Movahhed T; Abolhasani A; Daraei B; Dastmalchi S
Bioorg Med Chem; 2021 Feb; 32():115960. PubMed ID: 33477020
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy.
Ren SZ; Wang ZC; Zhu D; Zhu XH; Shen FQ; Wu SY; Chen JJ; Xu C; Zhu HL
Eur J Med Chem; 2018 Sep; 157():909-924. PubMed ID: 30149323
[TBL] [Abstract][Full Text] [Related]
5. The Effect of a Newly Synthesized Ferrocene Derivative against MCF-7 Breast Cancer Cells and Spheroid Stem Cells through ROS Production and Inhibition of JAK2/STAT3 Signaling Pathway.
Nourbakhsh M; Farzaneh S; Taghikhani A; Zarghi A; Noori S
Anticancer Agents Med Chem; 2020; 20(7):875-886. PubMed ID: 31893999
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, biological evaluation, and docking studies of some novel chalcones as selective COX-2 inhibitors.
Kaya Çavuşoğlu B; Sağlık BN; Acar Çevik U; Osmaniye D; Levent S; Özkay Y; Kaplancıklı ZA
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000273. PubMed ID: 33244799
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase-2 inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Dec; 13(23):6425-34. PubMed ID: 16099663
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors.
Zarghi A; Kakhgi S; Hadipoor A; Daraee B; Dadrass OG; Hedayati M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1336-9. PubMed ID: 18226898
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Biological Evaluation of New 1,3-diphenyl-3- (phenylamino)propan-1-ones as Selective Cyclooxygenase (COX-2) Inhibitors.
Farzaneh S; Shahhosseini S; Arefi H; Daraei B; Esfahanizadeh M; Zarghi A
Med Chem; 2018; 14(7):652-659. PubMed ID: 29804536
[TBL] [Abstract][Full Text] [Related]
10. Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2.
Shaker AMM; Shahin MI; AboulMagd AM; Abdel Aleem SA; Abdel-Rahman HM; Abou El Ella DA
Bioorg Chem; 2022 Dec; 129():106143. PubMed ID: 36191430
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives as cytotoxic agents and COX-2/LOX inhibitors.
Lamie PF; Philoppes JN; Rárová L
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700311. PubMed ID: 29400411
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of new 1,4-diarylazetidin-2-one derivatives (β-lactams) as selective cyclooxygenase-2 inhibitors.
Arefi H; Naderi N; Shemirani ABI; Kiani Falavarjani M; Azami Movahed M; Zarghi A
Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900293. PubMed ID: 31917485
[TBL] [Abstract][Full Text] [Related]
13. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
[TBL] [Abstract][Full Text] [Related]
14. A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway.
Noori S; Nourbakhsh M; Farzaneh S; Zarghi A
Anticancer Agents Med Chem; 2020; 20(18):2285-2292. PubMed ID: 32767949
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of new (E)- and (Z)-1,2,3-triaryl-2-propen-1-ones as selective COX-2 inhibitors.
Arfaie S; Zarghi A
Eur J Med Chem; 2010 Sep; 45(9):4013-7. PubMed ID: 20691338
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.
Rathore A; Rahman MU; Siddiqui AA; Ali A; Shaharyar M
Arch Pharm (Weinheim); 2014 Dec; 347(12):923-35. PubMed ID: 25303727
[TBL] [Abstract][Full Text] [Related]
17. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of new pyrazino[1,2-a]benzimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors.
Azami Movahed M; Daraei B; Shahosseini S; Esfahanizadeh M; Zarghi A
Arch Pharm (Weinheim); 2019 Feb; 352(2):e1800265. PubMed ID: 30561073
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R
Bioorg Med Chem; 2010 Aug; 18(16):5855-60. PubMed ID: 20650641
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors.
Coşkun GP; Djikic T; Hayal TB; Türkel N; Yelekçi K; Şahin F; Küçükgüzel ŞG
Molecules; 2018 Aug; 23(8):. PubMed ID: 30082676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
